Skip to main content
idi
Toggle navigation
0
You have 0 notifications
Site Visitor
Site Visitor
New To Inknowvation.com?
Register now to get an access to proprietary SBIR-STTR databases!
Registration is fast and free - start your access to business-actionable information today!
Login
Site Register
SBIR-STTR Award
You are here:
Home
Search Databases
Search SBIR-STTR Awards
SBIR-STTR Award
5
Development of Nanvas TM (Oil in Water Nanoemulsion Adjuvant) Formulated Allergens as Intranasal Immunotherapeutic Vaccines for Peanut Allergy
Award last edited on: 8/18/2020
Sponsored Program
SBIR
Awarding Agency
NIH
Total Award Amount
$299,888
Award Phase
1
Solicitation Topic Code
NIAID
Principal Investigator
Ali I Fattom
Company Information
BlueWillow Biologics Inc
(
AKA
: NanoBio Corporation)
2311 Green Road Suite A
Ann Arbor, MI 48107
(734) 302-4000
info@bluewillow.com
www.bluewillow.com
Location:
Single
Congr. District:
06
County:
Washtenaw
Phase I
Contract Number:
75N93019C00035
Start Date:
00/00/00
Completed:
00/00/00
Phase I year
2019
Phase I Amount
$299,888
Food allergy is an emerging health problem with increasing incidence and severityparticularly in childrenand continuing throughout adulthoodSincethe incidence of self reported peanut allergy has risen significantly representing a mounting financial burden to the healthcare systemWith no approved therapeutics availablevarious forms of immunotherapy have been evaluated but generally do not facilitate long term protection and can have adverse side effectsBlueWillow will apply its novel oil in water NanoVax nanoemulsion mucosal adjuvantNEto formulate an intranasal vaccine against peanut allergyNEfacilitates modulation of existing THimmune responses to promote THTHimmunityIn this Fasttrack proposalPhase I will establish compatibilityshort term vaccine stability and protection in a mouse model of peanut allergyIn phase IIwe will establish and optimize processes for scale upclinical lot manufacturing and long term stability of both antigen and final vaccine formulationassess the longterm protection in preclinical animal modelshold a pre IND meeting with the FDAand conduct a GLP safety toxicity studySuccessful completion of this project will enable IND filing and initiation of clinical trials to assess the intranasal peanutNEvaccineThis Peanut NEvaccine will be the first commercial vaccine available for the treatment of peanut allergies to address a significant unmet medical need
Phase II
Contract Number:
----------
Start Date:
00/00/00
Completed:
00/00/00
Phase II year
----
Phase II Amount
----
×
Login to your account
Mail sent successfully.
Enter any username and password.
Username
Password
Remember me
Login
Forgot your username?
Click here for assistance
Forgot your password?
Request new password
Don't have an account?
Sign up
Forgot username?
Mail sent successfully.
Enter username and password.
Please enter email address that is associated with your account.
Back
Submit
Still Need Help?
If you need further assistance, send us an
e-mail
and we will assist you in resetting your account.
Forgot password?
Mail sent successfully.
Enter username and password.
Please enter email address that is associated with your account.
Back
Submit
Still Need Help?
If you need further assistance, send us an
e-mail
and we will assist you in resetting your account.